Advanced Search
Contact | Corporate | Help

A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

Sponsors:
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Non-small Cell Lung Cancer
  • Brain Neoplasms
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: bevacizumab
  • Drug: erlotinib HCl
  • Drug: chemotherapy
Enrollment:
115

Additional information about NCT00312728.


SourceSolution © 2008-2012